OBJECTIVE: The current American Joint Committee on Cancer staging system for esophageal cancer is based on lymph node location, irrespective of the number of involved and examined lymph nodes. METHODS: We enrolled 488 patients receiving primary curative resection without neoadjuvant therapy for esophageal cancer between 1995 and 2006. The importance of total resected lymph node number (TLN) and metastatic lymph node number (MLN) and ratio (MLR) on patient survival was investigated. RESULTS: The overall 3-year survival rate was 35.4%. The 3-year survival rate was equivalent among patients in N1 (23.3%), M1a (22.0%), and nonregional lymph node metastasis-related M1b (18.5%, p = 0.321). No survival difference was noted between patients with TLN < 15 or > or =15 (p = 0.249). Both MLN and MLR significantly predicted patient survival. The 3-year survival rate was 52.3%, 29.2%, and 8.0% for patients with MLN = 0, 1-3, and > or =4, respectively (p < 0.001). For patients with MLR = 0-0.2 or >0.2, the 3-year survival rate was 28.7% and 9.8%, respectively (p < 0.001). However, survival rate differences were more evident when TLN was more than 15. CONCLUSIONS: We recommend designating both regional and nonregional lymph nodes as N nodes. MLN and MLR, but not TLN, are prognostic factors in esophageal cancer.
OBJECTIVE: The current American Joint Committee on Cancer staging system for esophageal cancer is based on lymph node location, irrespective of the number of involved and examined lymph nodes. METHODS: We enrolled 488 patients receiving primary curative resection without neoadjuvant therapy for esophageal cancer between 1995 and 2006. The importance of total resected lymph node number (TLN) and metastatic lymph node number (MLN) and ratio (MLR) on patient survival was investigated. RESULTS: The overall 3-year survival rate was 35.4%. The 3-year survival rate was equivalent among patients in N1 (23.3%), M1a (22.0%), and nonregional lymph node metastasis-related M1b (18.5%, p = 0.321). No survival difference was noted between patients with TLN < 15 or > or =15 (p = 0.249). Both MLN and MLR significantly predicted patient survival. The 3-year survival rate was 52.3%, 29.2%, and 8.0% for patients with MLN = 0, 1-3, and > or =4, respectively (p < 0.001). For patients with MLR = 0-0.2 or >0.2, the 3-year survival rate was 28.7% and 9.8%, respectively (p < 0.001). However, survival rate differences were more evident when TLN was more than 15. CONCLUSIONS: We recommend designating both regional and nonregional lymph nodes as N nodes. MLN and MLR, but not TLN, are prognostic factors in esophageal cancer.
Authors: M Tachibana; D K Dhar; S Kinugasa; T Kotoh; M Shibakita; S Ohno; R Masunaga; H Kubota; N Nagasue Journal: J Clin Gastroenterol Date: 2000-12 Impact factor: 3.062
Authors: R J Korst; V W Rusch; E Venkatraman; M S Bains; M E Burt; R J Downey; R J Ginsberg Journal: J Thorac Cardiovasc Surg Date: 1998-03 Impact factor: 5.209
Authors: Alexander J Greenstein; Virginia R Litle; Scott J Swanson; Celia M Divino; Stuart Packer; Juan P Wisnivesky Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: Wayne Hofstetter; Arlene M Correa; Neby Bekele; Jaffer A Ajani; Alexandria Phan; Ritsuko R Komaki; Zhongxing Liao; Dipen Maru; Tsung T Wu; Reza J Mehran; David C Rice; Jack A Roth; Ara A Vaporciyan; Garrett L Walsh; Ashleigh Francis; Shanda Blackmon; Stephen G Swisher Journal: Ann Thorac Surg Date: 2007-08 Impact factor: 4.330
Authors: Nasser K Altorki; Xi Kathy Zhou; Brendon Stiles; Jeffrey L Port; Subroto Paul; Paul C Lee; Madhu Mazumdar Journal: Ann Surg Date: 2008-08 Impact factor: 12.969
Authors: Danica N Giugliano; Adam C Berger; Michael J Pucci; Ernest L Rosato; Nathaniel R Evans; Hanna Meidl; Casey Lamb; Daniel Levine; Francesco Palazzo Journal: J Gastrointest Surg Date: 2017-06-29 Impact factor: 3.452
Authors: Sumanta Dutta; Andrew B C Crumley; Grant M Fullarton; Paul G Horgan; Donald C McMillan Journal: World J Surg Date: 2011-08 Impact factor: 3.352